Table 1. Percent reduction of B-cells antigens following overnight treatment of PBMCs.
| Treatment | CD22 | CD20 | CD19 | CD21 | CD79b | CD62L | CD44 | β7-Int |
| 22*-(20)-(20) | 96.2 (±1.3)a | n.d. | 83.9 (±6.2)c | 77.7 (±0.3)c | 61.7 (±7.9)a | 81.3 (±11.3)d | 51.0 (±6.5)d | 81.0 (±1.6)d |
| 22*-(19)-(19) | 93.7 (±1.6)b | 25.3 (±5.4)c | n.d. | 73.5 (±4.5)c | 42.0 (±6.7) | 64.5 (±7.0) | 30.45 (±5.2) | 57.7 (±3.5) |
| Epratuzumab | 92.5 (±2.1)b | 11.8 (±1.7) | 56.1 (±6.0) | 59.1 (±6.4) | 39.4 (±4.5) | 65.3 (±8.0) | 31.3 (±3.9) | 59.1 (±5.7) |
| Veltuzumab | 58.5 (±6.2) | n.d. | 92.9 (±2.3)a | 84.8 (±0.5)a | 45.0 (±10.3) | 77.5 (±7.2)e | 59.2 (±5.4)e | 83.1 (±2.1)e |
| hA19 | 29.0 (±3.4) | 17.3 (±8.2) | n.d. | 68.0 (±3.1)c | 32.8 (±7.6) | 52.6 (±5.8) | 31.9 (±4.6) | 42.8 (±3.4) |
Average % reduction from three experiments using PBMCs form independent donors. n.d., not measured due to blocked detection by the specific treatment. Significantly (P<0.05) more reduction than:
a
all other agents;
b
veltuzumab and hA19;
c
epratuzumab;
d
all but veltuzumab.
e
Not significantly different from 22*-(20)-(20).